Singapore
Intelligence de marché des dispositifs médicaux pour Singapore. Changements réglementaires, concurrents et tendances d'achats.
Signaux récents
A new AI device is being developed to assess difficult airways pre-operatively, aiding in surgical procedures.
Edwards Lifesciences LLC has registered a medical device with the FDA under product code LWR.
A novel microfluidic device is developed to capture circulating tumor cells for detecting EGFR mutations in NSCLC.
The CRYSTALSIGHT study is recruiting to evaluate a device for monitoring wet AMD recurrence using eye gaze tracking.
The semperguard skySense black, a Class I medical device, is registered by HARPS Investment Asia Pte. Ltd.
AeviceMD is a wearable device aimed at detecting wheeze in pediatric and adult populations during recruitment.
The study compares a microsieve device with a marker-based platform for isolating pancreatic cancer CTCs.
A study compares outcomes of a 3D-printed cranial orthosis with different donning methods post-craniectomy.
A completed study on a wearable magnetic flux device shows potential for blood pressure control in hypertensive patients.
The late feasibility study evaluated the AWAK PD device's safety and efficacy for end-stage kidney disease at home.
The WristBot is a robotic system for diagnosing and rehabilitating proprioceptive deficits post-stroke.
A mother discovered her son faced bullying after he intervened, leading to severe emotional distress and suicidal thoughts.
Singapore's GIC aims to support the growth of Japanese companies through strategic investments.
Despite the energy crisis in Asia, investors remain optimistic about market opportunities.
The 2026 ranking highlights fast-growing companies in the Asia-Pacific region.
Asia's manufacturing strengths may provide an advantage over the US in the evolving AI landscape.
Singapore leads in cyber defenses but ranks low in executive leadership on the issue.
Hong Kong and Singapore compete to be the launch pad for Chinese firms, with differing approaches to enterprise support.
Tranexamic acid can reduce maternal mortality during childbirth, but cost-effectiveness varies by region.
NTU Singapore's AI biochip detects microRNA biomarkers in 20 minutes using nanophotonics and deep learning.